The Small Business Innovation Research program is a United States Government program, managed by the Small Business Administration and intended to help small businesses conduct research and development of products that offer potential for commercialization. Funding to Shuttle Pharmaceuticals has been in the form of contracts for projects that meet U.S. government R&D needs.
Pola Pharma is a Japanese pharmaceutical company engaged in research and development, manufacture, sale and distribution of branded and generic products in Japan. Pola Pharma has licensed hypoxic radiation sensitizer technology to Shuttle Pharmaceuticals.
Propagenix is an R&D-stage cell therapy company engaged in the development and commercialization of cell growth technology developed at Georgetown University. Shuttle Pharmaceuticals sublicenses "conditional reprogramming cell" technology to enable the creation of cell lines for testing new and more effective drugs to enhance human healthcare.
Georgetown University is an internationally recognized educational and research university engaged in the discovery and develpment of new cancer diagnostics and therapeutics through the programs of the Lombardi Comprehensive Cancer Center. Shuttle Pharmaceuticals subcontracts clinical aspects of SBIR funded research to establish cancer cell lines from African-Americans patients and to develop predictive biomarkers for patient sensitivity to radiation late-effects.
University of Virginia
The University of Virginia is an internationally recognized educational and research university engaged in the discovery and development of new cancer therapeutics and has developed the "Atomic Radiation" intellectual property. Shuttle Pharmaceuticals holds an option to license the intellectual property for the development and commercialization of heavy oxygen containing radiation sensitizers.